Compare JBS N.V. Class A Common Shares (JBS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs TG Therapeutics Inc — how do they compare? JBS N.V. Class A Common Shares trades at $13.05 (market cap $13.96B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: JBS N.V. Class A Common Shares is the larger of the two by market cap, and JBS N.V. Class A Common Shares pays a 10.31% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and TG Therapeutics Inc for 16 Days on average.
| JBS | TGTX | |
|---|---|---|
Market Cap | $13.96B | $8.32B |
Volume | 5,326,589 | 1,285,303 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $59.06 |
52-Week Low | $10.86 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $34.93B | $8.52B |
Dividend Yield | 10.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
